Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Loss of ARPC1B impairs cytotoxic T lymphocyte maintenance and cytolytic activity
Lyra O. Randzavola, … , Taco W. Kuijpers, Gillian M. Griffiths
Lyra O. Randzavola, … , Taco W. Kuijpers, Gillian M. Griffiths
Published November 11, 2019
Citation Information: J Clin Invest. 2019;129(12):5600-5614. https://doi.org/10.1172/JCI129388.
View: Text | PDF
Research Article Cell biology Immunology Article has an altmetric score of 4

Loss of ARPC1B impairs cytotoxic T lymphocyte maintenance and cytolytic activity

  • Text
  • PDF
Abstract

CD8 cytotoxic T lymphocytes (CTLs) rely on rapid reorganization of the branched F-actin network to drive the polarized secretion of lytic granules, initiating target cell death during the adaptive immune response. Branched F-actin is generated by the nucleation factor actin-related protein 2/3 (Arp2/3) complex. Patients with mutations in the actin-related protein complex 1B (ARPC1B) subunit of Arp2/3 show combined immunodeficiency, with symptoms of immune dysregulation, including recurrent viral infections and reduced CD8+ T cell count. Here, we show that loss of ARPC1B led to loss of CTL cytotoxicity, with the defect arising at 2 different levels. First, ARPC1B is required for lamellipodia formation, cell migration, and actin reorganization across the immune synapse. Second, we found that ARPC1B is indispensable for the maintenance of TCR, CD8, and GLUT1 membrane proteins at the plasma membrane of CTLs, as recycling via the retromer and WASH complexes was impaired in the absence of ARPC1B. Loss of TCR, CD8, and GLUT1 gave rise to defects in T cell signaling and proliferation upon antigen stimulation of ARPC1B-deficient CTLs, leading to a progressive loss of CD8+ T cells. This triggered an activation-induced immunodeficiency of CTL activity in ARPC1B-deficient patients, which could explain the susceptibility to severe and prolonged viral infections.

Authors

Lyra O. Randzavola, Katharina Strege, Marie Juzans, Yukako Asano, Jane C. Stinchcombe, Christian M. Gawden-Bone, Matthew N.J. Seaman, Taco W. Kuijpers, Gillian M. Griffiths

×

Figure 4

Differential actin structure in hCTLs from ARPC1B-deficient patient.

Options: View larger image (or click on image) Download as PowerPoint
Differential actin structure in hCTLs from ARPC1B-deficient patient.
(A)...
(A) Immunoblot analysis of calnexin, ARPC1B, and ARPC1A in hCTL lysates from 4 different HD (lanes 1 to 4) and ARPC1B patient samples from day 20 (lanes 4 to 6) and day 12 (lanes 7 and 8) after expansion. HD 4 (lanes 4 and 7) was used for the rest of the study. MW markers in kD. Lanes were run on the same gel, but were noncontiguous. (B) Single plane of a Z-stack across hCTLs from HD or ARPC1B patient plated on ICAM-1– (0.5 μg/mL) or anti-CD3–coated (10 μg/mL; right panel) slide, fixed, stained with phalloidin and CD8 (not shown), and imaged using Structural Illumination Microscopy. Scale bars: 3 μm. (C) Quantitation of the mean intensity of phalloidin staining (F-actin) in HD or ARPC1B-deficient patient hCTLs generated from images as exemplified in B (right panel) (see Methods for description). HD n = 10 cells ARPC1B-patient n = 13 cells. ***P = 0.0053, unpaired t test. Data representative of 3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 6 X users
72 readers on Mendeley
See more details